Starting from commercially available educts, a straightforward synthetic route to new heterocyclic building blocks is exemplified with the one-or two-step synthesis of tri-, tetra-, or pentacyclic ring systems. Representatives of the following novel ring systems are prepared from 3-methyl-1-phenyl-2-pyrazolin-5-one and the corresponding o-haloarenecarbonyl chloride using calcium hydroxide in refluxing 1,4-dioxane: pyrimidino [4',5':5,6] While the latter two ring systems are directly obtained due to a spontaneous intramolecular substitution reaction, in the other reactions uncyclised 4-aroylpyrazol-5-ols are produced, which are cyclised into the target heterocycles in a subsequent synthetic step (i.e. treatment with NaH in DMF). Detailed NMR spectroscopic investigations ( 1 H-, 13 C-, 15 N-) with the obtained compounds were undertaken to unambiguously prove the new structures.
Introduction
The search for biologically active compounds is the driving force in pharmaceutical synthesis. Since the majority of new molecules entering clinical studies contains at least one heterocyclic moiety -predominantly N-heterocyclic ones [1] -the modification of these ring systems plays an important role during drug development [2, 3] . Thus, there is always a specific need for novel heterocyclic ring systems, both for finding new hit structures and in optimisation of lead compounds. Although theoretically unlimited, in practical terms and due to technical and economical reasons, only a very limited number of heterocycles is available for medicinal chemistry today. Our own interest in new and easily accessible heterocyclic building blocks stems from our ongoing research on xanthone (= dibenzo-γ-pyrone) derivatives, in which one of the benzene rings is replaced with a pyrazole nucleus and the other with a different heterocyclic moiety [4] [5] [6] . These interesting substructures occur in several bioactive compounds, such as in the anti-ulcer drug, amlexanox (Aphthasol™) [7, 8] or in the A 2 -subtype selective adenosine receptor antagonist A [9] (Figure 1 ). Consequently we investigated several synthetic strategies to facilitate alteration of this biologically interesting scaffold. While our primary research was based on synthetic approaches for the convenient variation of the substituents at the pyrazole core (in particular those of positions C-3, N-1 and N-2) [10, 11] , we turned our interest to the modification of the molecule's skeleton as well as the possibility of introducing substituents at other positions. The combination of these approaches would obviously allow access to specifically customised molecules. Nevertheless, only a few skeletons -mainly tricyclic ones like the possible four pyridines [4] -have been reported as successfully attempted up to the present.
Results and Discussion
The purpose of this study is to report the convenient one-or two-step synthesis of novel heterocyclic ring systems (Table 1) containing a [5, 6] pyrano [2,3-c] pyrazol-4(1H)-one moiety starting from commercially available educts. Thus, 2-pyrazolin-5-one 1 (a tautomer of 5-hydroxypyrazole [12] ) was reacted with the corresponding o-haloarenecarbonyl chlorides 2b-8b (Figure 2 ) in the presence of excess calcium hydroxide in boiling 1,4-dioxane (the 'Jensen' method [13] ) to affect the selective acylation at the pyrazole C-4. However, the target compounds 9 and 10 were directly obtained in the reaction of the acid chlorides 2b and 3b with pyrazolone 1, without isolation of the expected 4-aroylpyrazol-5-ols (Scheme 1). Obviously, spontaneous intramolecular cyclisation did occur (only) in these two cases, leading to formation of two new bonds (C-C and O-C, respectively) in a single reaction step in these molecules. This fact could be correlated with the activity towards nucleophilc aromatic substitution of the leaving halogen in the presumptive intermediates 21 and 22 ( Figure 3 ). In electron-rich aromatic compounds (which are known to be less reactive towards nucleophilic aromatic substitutions) such as thiophene derivatives 17-20 or even in the pyrimidine example 16 (where the halogen atom is situated meta to the activating N atom and hence the least active position in such pyridines), no cyclisation was observed. However, ring closure occurred spontaneously in the reactions of the acid chlorides 2b and 3b, in which the halogen was situated ortho or para to the activating N atom. This behaviour is in full agreement with the observations made in cyclisation reactions leading to different pyridino [5, 6] When the uncyclised intermediates were isolated, the transformation into the target ring systems was achieved by treatment of 4-aroylpyrazol-5-ols 16-20 with sodium hydride in refluxing dimethylformamide. * not isolated.
NMR spectroscopy
Recently, assignment of NMR signals (mainly 13 C-NMR lines) using prediction programs [14] such as CSEARCH [15] or ACD/C+H NMR Predictor [16] has become increasingly popular. However, the quality of such empirical predictions strongly depends on the availability in the corresponding databases of reliable material data from related structures. Thus, in cases where insufficient (or low quality) data is available for the description of a specific chemical environment, the prediction results are poor. The latter seems to be the case for many condensed heterocyclic systems containing few protons. This lack of high quality data provided the motivation for us to perform detailed NMR spectroscopic investigations of all novel compounds prepared and also their precursors. 13 C, 1 H spin coupling constants were also determined and unequivocally assigned by two-dimensional (δ, J) long-range INEPT spectra with selective excitation [24] . The 15 N-NMR spectra were mainly recorded using the gradient selected, sensitivity enhanced HMBC sequence [25] . The assignment of the numerous lines due to quaternary carbon atoms has not been a trivial task. For instance, in target compounds 9-15, the chemical shifts of the two carbon atoms directly attached to the pyran oxygen atom often closely resemble each other. Despite this fact, an unequivocal distinction was possible on basis of the 1 H-coupled 13 C-NMR spectra. The signal of the carbon atom located between pyrazole N-1 and the pyran oxygen always appears as a singlet, whereas the signal of the opposite pyran O-C atom is split by couplings to protons belonging to the system condensed on the 'right' side of the pyran ring. In compound 14 this diagnostic coupling is small ( 3 J C8b,H8 =1.0 Hz) and emerges only after pronounced resolution enhancement. Discrimination of C-5a vs. C-8a in 14, C-5a vs. C-10a in 15, and C-5 vs. C-7 in 13 is based on the upfield shift of the latter signal in each pair due to the influence of the pyran oxygen atom. In the fused pyrimidine derivative 11 the discrimination of the lines due to C-4a and C-8a (144.4 ppm, 146.0 ppm) is not possible considering the 1 H-coupled 13 C-NMR spectrum, since both signals show a 3 Hz splitting due to coupling with H-8. Here, unambiguous assignment of C-8a was achieved via a heteronuclear 13 C{ 1 H} NOE-difference experiment. Irradiation of the H-8 transition only enhanced the signal of the spatially close C-8a whereas the line of the more distant C-4a remained unaffected (Figure 3) . A similar approach was used to support the discrimination of the signals due to C-3a and C-6a in 4-acylpyrazolone 19 (enhancement of the C-3a signal after irradiation of H-4). In the latter compound, the signal of H-4 (attached to the carbon atom in β-position to the thiophene S-atom 6) can be simply distinguished from that of H-5 (attached to C-5, in α-position to S-6) considering the larger 1 Figure 4 . 13 C-NMR spectra (gated decoupling). 15 N-NMR spectra were obtained on a Bruker Avance 500 instrument with a 'directly' detecting broadband observe probe and were referenced against external nitromethane (coaxial capillary). Systematic names were generated with ACD/Name [26] according to the IUPAC recommendations and were also checked manually to ensure correct use of nomenclature within this publication [27] . All starting materials are commercially available and were purchased from Aldrich (1, 2a, 4a, 5a) , Fluorochem (8b), Frontier Scientific (6a), or Maybridge (3a, 7b), respectively. Product yields were not optimised.
o-Haloarenecarbonyl Chlorides 2b-6b: General Procedure.
A suspension of the commercially available o-haloarenecarboxylic acid 2a, 3a, 4a, 5a, or 6a (3 mmol) in toluene (10 mL), DMF (1 drop), and excess SOCl 2 (2 mL) were refluxed for 3 h. The solvent and excess SOCl 2 were removed under reduced pressure. Additional toluene (5 mL) was added and the solvent was removed under reduced pressure. The remaining acid chlorides of type b were used immediately, without further purification, in the next step. Commercially available acid chlorides 7b and 8b were used as purchased. Hitherto unpublished spectroscopic data of commercially available starting materials are presented below. Under anhydrous conditions, a solution/suspension of the corresponding o-haloarenecarbonyl chloride 2b-8b (3 mmol) in anhydrous 1,4-dioxane (3-5 mL) was added to a suspension of pyrazolone 1 (523 mg, 3 mmol) and Ca(OH) 2 (445 mg, 6 mmol) in anhydrous 1,4-dioxane (3-5 mL). The reaction mixture was heated at reflux under stirring for 3 h. After cooling to room temperature, the mixture was acidified with 2 M HCl (5-7 ml), stirred for 15 min, and poured into H 2 O (10-15 ml). After 30 min, solid products were filtered off, washed with H 2 O, and recrystallised. NMR data of compounds 9 and 10 are presented in Table 1 . [4',3':5,6] pyrano [2,3-c] [3,4-b] pyrazolo [4',3':5,6] pyrano [2,3-d] [2',3':5,6] pyrano [2,3-c] 
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